Ribomic Inc. (TYO:4591)

Japan flag Japan · Delayed Price · Currency is JPY
97.00
+6.00 (6.59%)
At close: Mar 6, 2026
Market Cap5.27B +46.9%
Revenue (ttm)750.00K -64.4%
Net Income-1.04B
EPS-22.12
Shares Out54.31M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,719,400
Average Volume3,408,345
Open91.00
Previous Close91.00
Day's Range90.00 - 100.00
52-Week Range72.00 - 141.00
Beta0.27
RSI63.77
Earnings DateFeb 12, 2026

About Ribomic

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Tokyo, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4591
Full Company Profile

Financial Performance

Financial Statements